Entecavir Bristol-Myers Squibb

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 617-621

  Billich, A ^a  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; ENTECAVIR; LAMIVUDINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

CHROMOSOME ABERRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; IC 50; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TESTIS DISEASE; TOXICITY TESTING; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DNA-DIRECTED DNA POLYMERASE; ENZYME INHIBITORS; GUANINE; HEPATITIS B; HERPES SIMPLEX; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034990695     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Metabolic studies on BMS-200475, a new antiviral compound with activity against hepatitis B virus
2. 4-Hydroxy-3-hydroxymethyl-2-methylenecyclopentylpurines and pyrimidines. A new class of anti-herpesvirus agents
3. 10th International Conference on Antiviral Research (Part II), Atlanta, GA, USA
4. 10th International Conference on Antiviral Research (Part III), Atlanta, GA, USA
5. BMS-200475, a new anti-hepatitis B compound, metabolic studies and comparison with 3TC, penciclovir and lobucavir
6. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro
7. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
8. Emerging Therapies for Chronic Viral Hepatitis Symposium, Montreal, Canada
9. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
10. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
11. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir
12. Clinical Microbiology and Infectious Diseases - Tenth European Congress (Part III), Stockholm, Sweden
13. Long-term therapy with entecavir (BMS-200475) in the woodchuck model of chronic hepatitis infection
14. Safety and efficacy of oral enticavir given for 28 days in subjects with chronic hepatitis B
15. Extra issue: New drugs R & D pipeline
16. Clinical potential of emerging new agents in hepatitis B
17. Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B
18. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis
19. Sustained antiviral efficacy in the woodchuck model of chronic hepatitis infection following long-term entecavir (BMS-200475) treatment
20. Modeling of viral decline in chronic hepatitis B patients during entecavir treatment
21. 'A strategy for growth': Investment community meeting
22. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance